-
Product Insights
NewTreatment Resistant Depression – Drugs In Development, 2024
Empower your strategies with our Treatment Resistant Depression – Drugs In Development, 2024 report and make more profitable business decisions. Treatment-resistant depression (TRD) refers to a form of depression that does not adequately respond to standard treatments, such as antidepressant medications or psychotherapy, even after multiple trials of different therapies. It can be a challenging and distressing condition for individuals experiencing persistent depressive symptoms. Some common characteristics of treatment-resistant depression include inadequate response to antidepressants; persistent symptoms, which can include feelings...
-
Product Insights
NewBipolar Disorder (Manic Depression) – Drugs In Development, 2024
Empower your strategies with our Bipolar Disorder (Manic Depression) – Drugs In Development, 2024 report and make more profitable business decisions. Bipolar disorder, previously known as manic depression, is a mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). These mood shifts can significantly impact a person's ability to function in daily life. The exact cause of bipolar disorder is not fully understood, but it is believed to involve a combination of...
-
Product Insights
NewMajor Depressive Disorder – Drugs In Development, 2024
Empower your strategies with our Major Depressive Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Major Depressive Disorder (MDD) is a common and severe mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. Symptoms may include changes in appetite and sleep patterns, fatigue, difficulty concentrating, feelings of worthlessness, and thoughts of death or suicide. Diagnosis is based on the duration and intensity of these symptoms....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ketamine in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ketamine in Bipolar Disorder (Manic Depression) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ketamine in Bipolar Disorder (Manic Depression)Drug Details:Ketamine is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ofev in Lymphangioleiomyomatosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ofev in Lymphangioleiomyomatosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ofev in Lymphangioleiomyomatosis Drug Details: Nintedanib (Ofev/Cyendiv) is a indolinone-derivative, acts as an...
-
Product Insights
Cancer Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cancer pain can be defined as a complex sensation that reflects both damages to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or skin, nerve, and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic, and neurosurgical pain management. The Cancer...
-
Product Insights
Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Its signs and symptoms include sleep disturbances, including insomnia or sleeping too much, appetite changes, anxiety, agitation, or restlessness, and physical problems like back pain or headaches. Depression can be treated via antidepressants, mood stabilizers, or antipsychotics. The Depression pipeline market research report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of...